Intuitive Surgical, Inc. $ISRG Stock Sold by Congress Asset Management Co.

Key Points

• Congress Asset Management Co. cut its Intuitive Surgical position by 89% in the third quarter, selling 267,849 shares and retaining 33,101 shares valued at approximately $13.46 million.
• Institutional investors own 83.64% of Intuitive Surgical, with several major firms—including Invesco, J. Stern & Co., and Arrowstreet Capital—boosting their holdings.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $502.53 price target, despite some recent target reductions and downgrades.

Congress Asset Management Co. reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 89.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,101 shares of the medical equipment provider's stock after selling 267,849 shares during the quarter. Congress Asset Management Co.'s holdings in Intuitive Surgical were worth $13,460,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp acquired a new position in Intuitive Surgical in the second quarter valued at $1,335,753,000. J. Stern & Co. LLP grew its holdings in shares of Intuitive Surgical by 18,504.6% during the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider's stock worth $1,204,788,000 after buying an additional 2,115,814 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Intuitive Surgical by 95.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider's stock worth $970,635,000 after buying an additional 1,027,475 shares during the last quarter. Polen Capital Management LLC acquired a new position in Intuitive Surgical in the 4th quarter valued at about $477,225,000. Finally, Invesco Ltd. increased its position in Intuitive Surgical by 17.4% in the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider's stock valued at $2,338,350,000 after acquiring an additional 611,268 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analyst commentary argues that Intuitive Surgical’s valuation multiple has contracted while the underlying business remains strong. Continued growth in da Vinci system placements, surgical procedures, instruments and recurring service revenue could support renewed earnings growth and a higher stock price. Intuitive Surgical: The Multiple Fell, The Story Didn't
• Positive Sentiment: GenAI is identified as a potential growth driver for medical-device companies including ISRG. Applications that improve surgical planning, operating-room efficiency or clinical decision-making could enhance adoption of robotic systems, although the opportunity is still developing. 3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes
• Neutral Sentiment: A Zacks industry outlook highlights Intuitive Surgical alongside Globus Medical and Thermo Fisher Scientific. The report points to medical-technology growth opportunities but also cautions that regulation, adoption costs and broader industry risks may affect how quickly new technologies translate into revenue. Zacks Industry Outlook
• Neutral Sentiment: ISRG recently recorded a sharp one-day advance that added roughly $6 billion to its market value, indicating renewed trading interest, but the move was not tied to a new earnings release or a clearly identified fundamental catalyst. Intuitive Surgical Price Swing

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wells Fargo & Company reaffirmed an "overweight" rating and set a $487.00 price objective (down from $654.00) on shares of Intuitive Surgical in a research report on Friday, July 17th. HSBC lowered Intuitive Surgical from a "buy" rating to a "hold" rating and set a $391.00 target price on the stock. in a report on Thursday, July 30th. Sanford C. Bernstein restated an "outperform" rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. BNP Paribas Exane raised Intuitive Surgical to an "outperform" rating in a report on Tuesday, July 28th. Finally, Mizuho set a $500.00 price objective on shares of Intuitive Surgical and gave the company a "neutral" rating in a research report on Wednesday, July 15th. Twenty-two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $502.53.

Insider Activity

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the transaction, the executive vice president directly owned 5,320 shares in the company, valued at approximately $2,016,280. This represents a 6.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $374.44, for a total transaction of $407,765.16. Following the completion of the transaction, the vice president directly owned 1,026 shares of the company's stock, valued at approximately $384,175.44. This trade represents a 51.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 12,370 shares of company stock valued at $4,891,989 in the last quarter. Insiders own 0.60% of the company's stock.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $404.76 on Wednesday. The stock's 50 day moving average price is $382.47 and its 200 day moving average price is $412.07. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88. The company has a market cap of $142.99 billion, a PE ratio of 46.36, a price-to-earnings-growth ratio of 3.07 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.48 by $0.32. The firm had revenue of $2.89 billion during the quarter, compared to analysts' expectations of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.Intuitive Surgical's revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.81 earnings per share. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company's products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.